Clinical Trials Browser

Phase 2 × Terminated × quizartinib × Clear all

NCT04209725 2023-12-05

A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Phase 2 Terminated

1 enrolled 7 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute